journal

Tumori | Page 3

journal
https://read.qxmd.com/read/31221037/unexpected-serious-aplastic-anemia-from-pd-1-inhibitors-beyond-what-we-know
#41
Marco Filetti, Raffaele Giusti, Arianna Di Napoli, Daniela Iacono, Paolo Marchetti
INTRODUCTION: The recent introduction of checkpoint inhibitor-based immunotherapy has revolutionized the treatment of advanced lung cancers, becoming standard of care in both first- and second-line treatment. New types of toxicity are emerging with the increasingly widespread use of these inhibitors. CASE PRESENTATION: We describe a case of aplastic anemia in a patient with stage IV non-small cell lung cancer after a single administration of nivolumab. CONCLUSIONS: Several similar case reports reported in literature show an increasing rate of toxicities from immunotherapy in this setting...
June 21, 2019: Tumori
https://read.qxmd.com/read/30474504/external-accelerated-partial-breast-irradiation-for-ductal-carcinoma-in-situ-long-term-follow-up-from-a-phase-3-randomized-trial
#42
RANDOMIZED CONTROLLED TRIAL
Carlotta Becherini, Icro Meattini, Lorenzo Livi, Pietro Garlatti, Isacco Desideri, Vieri Scotti, Lorenzo Orzalesi, Luis Jose Sanchez, Marco Bernini, Donato Casella, Silvia Nesi, Jacopo Nori, Simonetta Bianchi, Stefania Pallotta, Livia Marrazzo
INTRODUCTION: For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895). METHODS: Patients were treated in a phase 3 randomized trial comparing whole breast irradiation (50 Gy in 25 fractions to the whole breast, plus 10 Gy in 5 fractions to the tumor bed) to APBI (30 Gy in 5 nonconsecutive fractions) using the intensity-modulated radiotherapy technique...
June 2019: Tumori
https://read.qxmd.com/read/29911501/vision-2030-for-the-optimal-approach-to-cancer-research-and-care-in-europe-a-mission-or-a-network-of-networks
#43
Thierry Philip, Geneviève Almouzni, Philip Poortmans
INTRODUCTION: A mission-oriented approach to cancer care in Europe was proposed by Julio Celis and Dainius Pavalkis in 2017. The major proposed objective is to achieve long-term survival of 3 out of 4 cancer patients by 2030. BACKGROUND: The authors are president or president-elect of Organization of European Cancer Institutes (OECI) EU Life or European Cancer Community Organization (ECCO). RESULTS: The goal is laudable and ambitious. However, it can only be successful if it is coordinated with active involvement of all stakeholders and interacts with an already well-organized, recognized, and certified European Accreditation and Designation quality approach to identify and select the potential candidates to participate in such a virtual network...
June 2019: Tumori
https://read.qxmd.com/read/31099306/the-essential-role-of-prevention-in-reducing-the-cancer-burden-in-europe-a-commentary-from-cancer-prevention-europe
#44
Carolina Espina, Linda Bauld, Bernardo Bonanni, Hermann Brenner, Karen Brown, Joakim Dillner, Ellen Kampman, Mef Nilbert, Paolo Vineis, Matty P Weijenberg, Alison Cox, Theo M de Kok, Daniela Fecht, Giota Mitrou, David C Muller, Davide Serrano, Karen Steindorf, Hans Storm, Mangesh A Thorat, Fränzel van Duijnhoven, Elisabete Weiderpass, Joachim Schüz
No abstract text is available yet for this article.
May 17, 2019: Tumori
https://read.qxmd.com/read/31096849/radium-223-for-the-treatment-of-bone-metastases-in-castration-resistant-prostate-cancer-when-and-why
#45
Rosj Gallicchio, Pietro A Mastrangelo, Anna Nardelli, Pier Paolo Mainenti, Antonio P Colasurdo, Matteo Landriscina, Giuseppe Guglielmi, Giovanni Storto
Radium-223 dichloride (223 Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223 Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223 Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events...
May 16, 2019: Tumori
https://read.qxmd.com/read/31088341/female-breast-cancers-t1-2-n0-m0-hr-her2-with-an-intermediate-genetic-based-recurrence-risk-a-real-world-estimate-in-italy
#46
Emanuele Crocetti, Alessandra Ravaioli, Dino Amadori, Silvia Mancini, Rosa Vattiato, Orietta Giuliani, Flavia Baldacchini, Fabio Falcini
OBJECTIVES: Prognostic definition and treatment of breast cancer are supported by multigene testing. A recent trial (TAILORx) provided evidence against the use of adjuvant chemotherapy in early breast cancer (HR+ HER2-) with an intermediate result (11-25) in a multigene test (Oncotype DX). These results consequently fueled great discussion among oncologists. We aimed to estimate the burden of Italian incident breast cancer patients who, each year, may be involved in such decision-making...
May 15, 2019: Tumori
https://read.qxmd.com/read/31072230/thrombosis-of-the-dorsal-vein-of-the-penis-as-first-clinical-presentation-of-pancreatic-cancer-metastatic-to-the-penis
#47
Matteo Virdis, Cristiana Bonifacio, Tatiana Brambilla, Giovanni Capretti, Pasquale De Nittis, Fara Uccelli, Alessandro Zerbi
INTRODUCTION: Though metastatic disease is a common presentation of pancreatic adenocarcinoma, localization to the penis is an extremely rare event despite its abundant vascularization. Primary cancers responsible for penile metastases usually occur in prostate and rectum and are often associated with disseminated malignancy and poor prognosis. CASE DESCRIPTION: A 66-year-old man was diagnosed with adenocarcinoma of the tail of the pancreas after the onset of thrombosis of the dorsal vein of the penis; pubis ultrasound and total body computed tomography scan were negative for metastases at other sites...
May 9, 2019: Tumori
https://read.qxmd.com/read/31068090/development-technical-validation-and-clinical-application-of-a-multigene-panel-for-hereditary-gastrointestinal-cancer-and-polyposis
#48
Maria Teresa Ricci, Sara Volorio, Stefano Signoroni, Paolo Mariani, Frederique Mariette, Domenico Sardella, Valeria Pensotti, Marco Vitellaro
INTRODUCTION: Recent advances in technology and research are rapidly changing the diagnostic approach to hereditary gastrointestinal cancer (HGIC) syndromes. Although the practice of clinical genetics is currently transitioning from targeted criteria-based testing to multigene panels, important challenges remain to be addressed. The aim of this study was to develop and technically validate the performance of a multigene panel for HGIC. METHODS: CGT-colon-G14 is an amplicon-based panel designed to detect single nucleotide variants and small insertions/deletions in 14 well-established or presumed high-penetrance genes involved in HGIC...
May 8, 2019: Tumori
https://read.qxmd.com/read/31041885/comparison-of-ultra-low-dose-chest-ct-scanning-protocols-for-the-detection-of-pulmonary-nodules-a-phantom-study
#49
Milanese Gianluca, Silva Mario, Frauenfelder Thomas, Eberhard Matthias, Sabia Federica, Martini Chiara, Marchianò Alfonso, Prokop Mathias, Sverzellati Nicola, Pastorino Ugo
PURPOSE: To test ultra-low-dose computed tomography (ULDCT) scanning protocols for the detection of pulmonary nodules (PN). METHODS: A chest phantom containing 19 solid and 11 subsolid PNs was scanned on a third-generation dual-source computed tomography (CT) scanner. Five ULDCT scans (Sn100kVp and 120, 70, 50, 30, and 20 reference mAs, using tube current modulation), reconstructed with iterative reconstruction (IR) algorithm at strength levels 2, 3, 4, and 5, were compared with standard CT (120kVp, 150 reference mAs, using tube current modulation)...
May 1, 2019: Tumori
https://read.qxmd.com/read/31041884/flower-cells-of-tropical-descent-a-challenging-case-of-adult-t-cell-leukemia-lymphoma
#50
Giovanni Martino, Magda Zanelli, Andrea Marra, Martina Quintini, Maurizio Zizzo, Stefano Ascani, Maria Paola Martelli, Brunangelo Falini
BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease associated with human T-lymphotropic virus type 1 infection, with a very high prevalence in tropical areas but exceptionally rare in Europe and Western countries. CASE PRESENTATION: We describe a challenging case of ATLL in a young male patient with Brazilian origin and adopted as a child by an Italian family, presenting to our clinic with atypical T-lymphocytosis and life-threatening lung infections...
May 1, 2019: Tumori
https://read.qxmd.com/read/31023193/diary-of-a-journey-to-a-faraway-galaxy
#51
Andrea Ferrari, Laura Veneroni, Anna Romani, Elena Pagani Bagliacca, Paola Gaggiotti, Matteo Silva, Stefano Signoroni, Maura Massimino
This article describes a brief account written by a girl treated with chemotherapy and surgery for an ovarian germ cell tumor. The brief novel was conceived in the context of the Youth Project of Milan, dedicated to helping adolescent and young adult cancer patients socialize and express themselves through group activities that focus on art and creativity. It describes the scenery of a new galaxy and is replete with images and metaphors that recall the experience of receiving anticancer treatment, touching on emotional themes including desire, isolation, fear, and hope...
April 26, 2019: Tumori
https://read.qxmd.com/read/31023173/complete-remission-for-4-years-with-crizotinib-in-advanced-alk-positive-non-small-cell-lung-cancer-after-thoracostomy-for-empyema
#52
Eufra Van Damme, Maja Kiselinova, Elke Van Schoote
INTRODUCTION: Anaplastic lymphoma kinase ( ALK) gene translocation occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC), typically in younger patients. Crizotinib (tyrosine kinase inhibitor) has been considered as the standard of care for advanced ALK-positive lung cancer but it only gives a median progression-free survival of 7.7-11 months. CASE: A 41-year-old old man, former smoker, was diagnosed with NSCLC in the right lung with manifest pleural effusion...
April 26, 2019: Tumori
https://read.qxmd.com/read/30967031/the-italian-rare-pancreatic-exocrine-cancer-initiative
#53
Oronzo Brunetti, Claudio Luchini, Antonella Argentiero, Stefania Tommasi, Anita Mangia, Giuseppe Aprile, Paolo Marchetti, Enrico Vasile, Andrea Casadei Gardini, Mario Scartozzi, Sandro Barni, Sara Delfanti, Fernando De Vita, Francesco Di Costanzo, Michele Milella, Chiara Alessandra Cella, Rossana Berardi, Ivana Cataldo, Daniele Santini, Claudio Doglioni, Evaristo Maiello, Rita T Lawlor, Vincenzo Mazzaferro, Sara Lonardi, Felice Giuliante, Giovanni Brandi, Aldo Scarpa, Stefano Cascinu, Nicola Silvestris
INTRODUCTION: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices...
April 9, 2019: Tumori
https://read.qxmd.com/read/30945623/short-course-olanzapine-to-prevent-delayed-emesis-following-carboplatin-paclitaxel-for-gynecologic-cancer-a-randomised-study
#54
Luigi Celio, Gabriella Saibene, Stefano Lepori, Fabrizio Festinese, Monica Niger, Francesco Raspagliesi, Domenica Lorusso
PURPOSE: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. METHODS: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27)...
April 4, 2019: Tumori
https://read.qxmd.com/read/30945608/clinical-characteristics-and-prognosis-associated-with-multiple-primary-malignant-tumors-in-non-hodgkin-lymphoma-patients
#55
Yanan Jiang, Zhaoyi Miao, Jinhuan Wang, Jing Chen, Yangyang Lv, Donghui Xing, Xiaofang Wang, Yafei Wang, Zeng Cao, Zhigang Zhao
OBJECTIVE: Patients with non-Hodgkin lymphoma (NHL) occasionally present with multiple primary malignant tumors (MPMTs). This study aimed to determine the clinical characteristics, survival, and risk factors of these patients. METHODS: The median follow-up of 92 patients was 13.5 months (range 0.3-72). Overall, 21 patients had synchronous MPMTs and 71 had metachronous MPMTs. We classified patients in the latter group into metachronous first group (n=27) and metachronous second group (n=44)...
April 4, 2019: Tumori
https://read.qxmd.com/read/30940005/anesthetic-management-of-radical-nephrectomy-in-patients-with-renal-cell-carcinoma-involving-renal-vein-or-inferior-vena-cava
#56
Kun Chen, Juan Wang, Jinzhen Dai, Ailin Luo, Yuke Tian, Zhonghui Guan, Xueren Wang
OBJECTIVE: To investigate the perioperative anesthetic management of patients diagnosed with renal cell carcinoma (RCC) metastasized into the renal vein or inferior vena cava (IVC) after undergoing radical nephrectomy to provide clinical evidence for rational anesthetic interventions. METHODS: A total of 81 patients with RCC extending into the renal vein or IVC, aged 17-73 years, undergoing radical nephrectomy were recruited. Preoperative status, intraoperative management, average operation time, average estimated blood loss, postanesthesia outcomes, and postoperative complications were retrospectively analyzed...
April 2, 2019: Tumori
https://read.qxmd.com/read/30935343/fulminant-blast-crisis-with-de-novo-11q23-rearrangement-in-a-philadelphia-positive-cml-patient-undergoing-treatment-with-dasatinib
#57
Snjezana Janjetovic, Anne Marie Asemissen, Frank Dicker, Mascha Binder, Judith Dierlamm, Carsten Bokemeyer, Philippe Schafhausen
BACKGROUND: Progression of chronic myeloid leukemia (CML) is frequently accompanied by cytogenetic evolution, with an extra copy of the Philadelphia chromosome, trisomy 8 and 19, and isochromosome (17p) commonly detected. Translocations involving 11q23 chromosomal region have been rarely reported in CML. The few reported patients with blast crisis (BC) of CML carrying an 11q rearrangement have insufficient responses to tyrosine kinase inhibitors (TKIs) and possess a poor prognosis. CASE REPORT: We report the case of a 30-year-old man with CML who had a fulminant myeloid BC 4 months after initiation of first-line therapy with the TKI dasatinib, despite showing an optimal response at the 3-month timepoint...
April 1, 2019: Tumori
https://read.qxmd.com/read/30935289/impact-of-tumor-site-on-the-prognosis-of-small-bowel-adenocarcinoma
#58
Rosa Falcone, Adriana Romiti, Marco Filetti, Michela Roberto, Riccardo Righini, Andrea Botticelli, Emanuela Pilozzi, Michele Ghidini, Claudio Pizzo, Federica Mazzuca, Paolo Marchetti
BACKGROUND: Because of a lack of large-scale prospective studies there is no clear indication about the management of patients with small bowel adenocarcinoma (SBA). This study evaluated clinical outcome of patients diagnosed with SBA at our institution. METHODS: Clinicopathologic features, treatments, and clinical outcome of patients diagnosed with SBA between 2006 and 2017 were retrospectively analyzed. Median time of survival was calculated and compared using the log-rank test...
April 1, 2019: Tumori
https://read.qxmd.com/read/30935288/hepatitis-d-reactivation-in-a-patient-with-metastatic-renal-cell-carcinoma-receiving-sunitinib-therapy
#59
Emre Akar, Mehmet Haluk Yücel, Tunahan Şahin, Deniz Tural
BACKGROUND: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. CASE REPORT: A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib...
April 1, 2019: Tumori
https://read.qxmd.com/read/30931812/clinical-features-and-treatment-of-patients-with-lung-adenocarcinoma-with-bone-marrow-metastasis
#60
Di Wang, Yang Luo, Di Shen, Lin Yang, Hui-Ying Liu, Yi-Qun Che
BACKGROUND: Bone marrow metastasis occurs in lung adenocarcinoma patients with a poor prognosis due to the late course and lack of definitive treatments, although reports on this are limited. This study analyzed the clinical manifestation, laboratory examination, treatment, and prognosis of patients with lung adenocarcinoma with bone marrow metastasis. METHODS: All patients were confirmed to have bone marrow infiltration by bone marrow aspiration. The clinical data of 12 patients with lung adenocarcinoma with bone marrow metastasis were analyzed retrospectively...
April 1, 2019: Tumori
journal
journal
21682
3
4
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"